Corcept Therapeutics Incorporated (0I3Q.L)
USD 67.86
(2.8%)
USD 67.86
(2.8%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 107.28 Million USD | -4.75% |
| 2022 | 112.63 Million USD | -9.51% |
| 2021 | 124.47 Million USD | -2.91% |
| 2020 | 128.2 Million USD | 14.87% |
| 2019 | 111.6 Million USD | 24.71% |
| 2018 | 89.49 Million USD | 69.32% |
| 2017 | 52.85 Million USD | 419.26% |
| 2016 | 10.17 Million USD | 395.64% |
| 2015 | -3.44 Million USD | 87.53% |
| 2014 | -27.61 Million USD | 33.44% |
| 2013 | -41.49 Million USD | -14.4% |
| 2012 | -36.27 Million USD | -12.19% |
| 2011 | -32.33 Million USD | -17.84% |
| 2010 | -27.43 Million USD | -35.49% |
| 2009 | -20.25 Million USD | -2.85% |
| 2008 | -19.68 Million USD | -60.79% |
| 2007 | -12.24 Million USD | 52.13% |
| 2006 | -25.58 Million USD | -20.91% |
| 2005 | -21.15 Million USD | -31.87% |
| 2004 | -16.04 Million USD | -60.54% |
| 2003 | -9.99 Million USD | 46.82% |
| 2002 | -18.79 Million USD | -134.76% |
| 2001 | -8 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 29.5 Million USD | -6.85% |
| 2024 Q2 | 35.59 Million USD | 20.65% |
| 2024 Q3 | 46.59 Million USD | 30.92% |
| 2023 Q3 | 31.17 Million USD | 5.39% |
| 2023 Q1 | 14.85 Million USD | -33.98% |
| 2023 FY | 107.28 Million USD | -4.75% |
| 2023 Q2 | 29.58 Million USD | 99.17% |
| 2023 Q4 | 31.66 Million USD | 1.58% |
| 2022 Q3 | 31.93 Million USD | 1.6% |
| 2022 Q1 | 26.76 Million USD | -26.99% |
| 2022 Q4 | 22.49 Million USD | -29.55% |
| 2022 FY | 112.63 Million USD | -9.51% |
| 2022 Q2 | 31.43 Million USD | 17.42% |
| 2021 Q4 | 36.66 Million USD | 1.19% |
| 2021 Q3 | 36.23 Million USD | 13.43% |
| 2021 Q2 | 31.94 Million USD | 62.66% |
| 2021 FY | 124.47 Million USD | -2.91% |
| 2021 Q1 | 19.63 Million USD | -35.63% |
| 2020 FY | 128.2 Million USD | 14.87% |
| 2020 Q3 | 24.71 Million USD | -29.9% |
| 2020 Q2 | 35.26 Million USD | -6.49% |
| 2020 Q1 | 37.71 Million USD | 7.7% |
| 2020 Q4 | 30.51 Million USD | 23.43% |
| 2019 FY | 111.6 Million USD | 24.71% |
| 2019 Q2 | 24.63 Million USD | 29.95% |
| 2019 Q1 | 18.95 Million USD | -23.87% |
| 2019 Q4 | 35.01 Million USD | 6.1% |
| 2019 Q3 | 33 Million USD | 33.98% |
| 2018 Q4 | 24.89 Million USD | 8.4% |
| 2018 FY | 89.49 Million USD | 69.32% |
| 2018 Q2 | 20.63 Million USD | -1.72% |
| 2018 Q3 | 22.96 Million USD | 11.32% |
| 2018 Q1 | 20.99 Million USD | -3.24% |
| 2017 Q4 | 21.69 Million USD | 59.27% |
| 2017 Q2 | 12.79 Million USD | 169.94% |
| 2017 Q3 | 13.62 Million USD | 6.47% |
| 2017 FY | 52.85 Million USD | 419.26% |
| 2017 Q1 | 4.74 Million USD | -5.33% |
| 2016 Q1 | 592 Thousand USD | -64.14% |
| 2016 Q2 | 1.5 Million USD | 154.73% |
| 2016 Q3 | 3.07 Million USD | 103.71% |
| 2016 Q4 | 5 Million USD | 62.99% |
| 2016 FY | 10.17 Million USD | 395.64% |
| 2015 Q3 | 102 Thousand USD | 108.75% |
| 2015 Q4 | 1.65 Million USD | 1518.63% |
| 2015 Q2 | -1.16 Million USD | 71.07% |
| 2015 FY | -3.44 Million USD | 87.53% |
| 2015 Q1 | -4.03 Million USD | -30.97% |
| 2014 Q2 | -6.58 Million USD | 48.82% |
| 2014 Q3 | -5.1 Million USD | 22.46% |
| 2014 FY | -27.61 Million USD | 33.44% |
| 2014 Q4 | -3.07 Million USD | 39.7% |
| 2014 Q1 | -12.85 Million USD | -28.21% |
| 2013 Q2 | -10.78 Million USD | 1.46% |
| 2013 FY | -41.49 Million USD | -14.4% |
| 2013 Q4 | -10.03 Million USD | -2.98% |
| 2013 Q3 | -9.74 Million USD | 9.67% |
| 2013 Q1 | -10.94 Million USD | -9.65% |
| 2012 Q3 | -7.67 Million USD | -1.04% |
| 2012 Q2 | -7.59 Million USD | 31.16% |
| 2012 FY | -36.27 Million USD | -12.19% |
| 2012 Q1 | -11.02 Million USD | -11.09% |
| 2012 Q4 | -9.98 Million USD | -30.1% |
| 2011 Q2 | -8.86 Million USD | -24.95% |
| 2011 FY | -32.33 Million USD | -17.84% |
| 2011 Q1 | -7.09 Million USD | 9.28% |
| 2011 Q4 | -9.92 Million USD | -54.23% |
| 2011 Q3 | -6.43 Million USD | 27.42% |
| 2010 Q4 | -7.82 Million USD | -10.12% |
| 2010 FY | -27.43 Million USD | -35.49% |
| 2010 Q3 | -7.1 Million USD | -10.24% |
| 2010 Q2 | -6.44 Million USD | -6.28% |
| 2010 Q1 | -6.06 Million USD | -17.45% |
| 2009 Q4 | -5.16 Million USD | -10.56% |
| 2009 FY | -20.25 Million USD | -2.85% |
| 2009 Q3 | -4.67 Million USD | 4.34% |
| 2009 Q2 | -4.88 Million USD | 11.78% |
| 2009 Q1 | -5.53 Million USD | 8.03% |
| 2008 Q3 | -4.9 Million USD | -4.59% |
| 2008 Q2 | -4.68 Million USD | -14.79% |
| 2008 Q1 | -4.08 Million USD | 7.6% |
| 2008 FY | -19.68 Million USD | -60.79% |
| 2008 Q4 | -6.01 Million USD | -22.75% |
| 2007 Q3 | -3.61 Million USD | -129.13% |
| 2007 Q4 | -4.41 Million USD | -22.14% |
| 2007 FY | -12.24 Million USD | 52.13% |
| 2007 Q1 | -2.62 Million USD | 34.15% |
| 2007 Q2 | -1.57 Million USD | 39.92% |
| 2006 Q3 | -6.54 Million USD | 18.79% |
| 2006 Q2 | -8.06 Million USD | -15.55% |
| 2006 Q4 | -3.99 Million USD | 39.06% |
| 2006 Q1 | -6.97 Million USD | -26.78% |
| 2006 FY | -25.58 Million USD | -20.91% |
| 2005 Q3 | -5.48 Million USD | -24.97% |
| 2005 Q1 | -5.78 Million USD | -4.79% |
| 2005 FY | -21.15 Million USD | -31.87% |
| 2005 Q4 | -5.5 Million USD | -0.44% |
| 2005 Q2 | -4.38 Million USD | 24.21% |
| 2004 Q4 | -5.52 Million USD | -29.7% |
| 2004 FY | -16.04 Million USD | -60.54% |
| 2004 Q2 | -3.69 Million USD | -43.75% |
| 2004 Q3 | -4.25 Million USD | -15.25% |
| 2004 Q1 | -2.57 Million USD | -25.76% |
| 2003 Q2 | -2.92 Million USD | -1.99% |
| 2003 Q4 | -2.04 Million USD | 5.47% |
| 2003 Q3 | -2.16 Million USD | 26.03% |
| 2003 FY | -9.99 Million USD | 46.82% |
| 2003 Q1 | -2.86 Million USD | 0.0% |
| 2002 FY | -18.79 Million USD | -134.76% |
| 2001 FY | -8 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 98.436% |
| Dynavax Technologies Corporation | -37.02 Million USD | 389.732% |
| Illumina, Inc. | -1.06 Billion USD | 110.036% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 94.573% |
| Biogen Inc. | 1.29 Billion USD | 91.727% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 123.294% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 90.133% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 140.057% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 2136.098% |
| Waters Corporation | 817.67 Million USD | 86.88% |
| Perrigo Company plc | 151.9 Million USD | 29.373% |
| uniQure N.V. | -282.87 Million USD | 137.926% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 127.404% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 245.974% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 138.869% |
| bluebird bio, Inc. | -244.26 Million USD | 143.921% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 188.302% |
| Imunon, Inc. | -21.03 Million USD | 610.127% |
| Myriad Genetics, Inc. | -123.7 Million USD | 186.728% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 57.241% |
| Nektar Therapeutics | -137.42 Million USD | 178.066% |
| Editas Medicine, Inc. | -169.18 Million USD | 163.413% |
| Verastem, Inc. | -92.08 Million USD | 216.504% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 100.762% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 337.996% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 196.987% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 340.182% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 44.825% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 139.153% |
| Evolus, Inc. | -49.23 Million USD | 317.907% |
| Adicet Bio, Inc. | -152.03 Million USD | 170.563% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 210.194% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 97.349% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 168.964% |
| FibroGen, Inc. | -281.81 Million USD | 138.068% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 92.053% |
| OPKO Health, Inc. | -157.02 Million USD | 168.323% |
| Homology Medicines, Inc. | -48.25 Million USD | 322.323% |
| Geron Corporation | -193.94 Million USD | 155.316% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 138.02% |
| Exelixis, Inc. | 170.88 Million USD | 37.22% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 206.402% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 292.413% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 120.82% |
| Zoetis Inc. | 3.06 Billion USD | 96.504% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 146.277% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 322.577% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 97.509% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 374.007% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 130.329% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 68.22% |
| Blueprint Medicines Corporation | -486.27 Million USD | 122.062% |
| Insmed Incorporated | -709.62 Million USD | 115.118% |
| TG Therapeutics, Inc. | 20.63 Million USD | -419.953% |
| Incyte Corporation | 620.52 Million USD | 82.711% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 114.769% |